Efficacy and safety of phosphodiesterase type 5 inhibitors and selective serotonin reuptake inhibitors in the treatment of comorbiditiy of erectile dysfunction and premature ejaculation: a meta analysis
10.3969/j.issn.1009-8291.2023.10.014
- VernacularTitle:磷酸二酯酶-5型抑制剂与五羟色胺再摄取抑制剂治疗勃起功能障碍合并早泄疗效及安全性Meta分析
- Author:
Deyu MIAO
1
,
2
;
Zulong WANG
3
;
Chenming ZHANG
4
;
Wenxi WAN
1
,
2
Author Information
1. The First Clinical Medical School of Henan University of Chinese Medicine, Zhengzhou 450099
2. Department of Andrology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450003
3. Department of Andrology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450003
4. The Second Clinical Medical School of Henan University of Chinese Medicine, Zhengzhou 450053, China
- Publication Type:Journal Article
- Keywords:
erectile dysfunction;
premature ejaculation;
Meta analysis;
phosphodiesterase type 5 inhibitor;
selective serotonin reuptake inhibitors
- From:
Journal of Modern Urology
2023;28(10):888-893
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To evaluate the efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors alone or in combination with selective serotonin reuptake inhibitors (SSRIs) compared with SSRIs alone in the treatment of comorbidity of erectile dysfunction (ED) and premature ejaculation (PE). 【Methods】 The clinical randomized controlled trials of ED and PE comorbidity treated with PDE5 inhibitors alone or in combination with SSRIs were searched from database inception to Sep.2022, in CNKI, PubMed, Web of Science, Embase, Wanfang Database, cqVIP Database, SinoMed and Yiigle. The intravaginal ejaculatory latency time(IELT), score of International Index of Erectile Function 5 (IIEF-5) and adverse reaction rate were analyzed with RevMan 5.4.1 software. 【Results】 A total of9 studies involving 793 patients were included. Meta analysis showed that compared with SSRIs alone, PDE5 inhibitors alone or in combination with SSRIs yielded better results in IELT [MD=1.99, 95%CI(1.51-2.46), P<0.001] and higher IIEF-5 score [MD=4.61, 95%CI(3.68-5.55), P<0.001] , but no increase in adverse events [RR=0.99, 95%CI(0.74-1.31), P=0.92] . 【Conclusion】 In the treatment of ED and PE comorbidity, priority should be given to ED or both ED and PE, which can produce better efficacy without increasing the adverse effects.
